NCT00592969 is a Phase 4 clinical trial of metformin in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT00592969?

NCT00592969 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT00592969?

Interventions in NCT00592969: metformin, biphasic insulin aspart.

What condition does NCT00592969 study?

NCT00592969 studies Diabetes, Diabetes Mellitus, Type 2.

Is NCT00592969 still recruiting?

NCT00592969 is currently completed. Last updated 24 February 2017.

Last reviewed 2017-02-24 · How we verify

NCT00592969

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes

Completed Phase 4 Last updated 24 February 2017

What this trial tests

Phase 4 trial testing metformin in Diabetes in 164 participants. Completed in 2 November 2004.

Timeline

3 December 2003

Primary endpoint
2 November 2004

2 November 2004

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	164
Start date	3 December 2003
Primary completion	2 November 2004
Estimated completion	2 November 2004
Sites	2 locations across Argentina, Brazil

Drugs / interventions tested

metformin (metformin) — full drug profile →
biphasic insulin aspart — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

18 and older, any sex, with Diabetes or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in South America. The aim of this trial is to evaluate the efficacy of metformin plus biphasic insulin aspart or insulin NPH on blood glucose control in subjects with type 2 diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of metformin

Trials testing the same drug.

NCT06463743 — Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) · Phase 2 · recruiting
NCT06679413 — A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants · Phase 1 · completed
NCT05966792 — SGLT2 Inhibitors in Treating Patients With PCOS · NA · completed
NCT05767515 — The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS · NA · completed
NCT05815680 — A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overw · Phase 1 · completed

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00592969 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 24 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00592969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing